JP2021501806A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501806A5
JP2021501806A5 JP2020544335A JP2020544335A JP2021501806A5 JP 2021501806 A5 JP2021501806 A5 JP 2021501806A5 JP 2020544335 A JP2020544335 A JP 2020544335A JP 2020544335 A JP2020544335 A JP 2020544335A JP 2021501806 A5 JP2021501806 A5 JP 2021501806A5
Authority
JP
Japan
Prior art keywords
azaspiro
cyclopropyl
isoxazole
carboxylic acid
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501806A (ja
JP7228595B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058326 external-priority patent/WO2019089672A1/en
Publication of JP2021501806A publication Critical patent/JP2021501806A/ja
Publication of JP2021501806A5 publication Critical patent/JP2021501806A5/ja
Application granted granted Critical
Publication of JP7228595B2 publication Critical patent/JP7228595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544335A 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしてのスピロ環化合物 Active JP7228595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580068P 2017-11-01 2017-11-01
US62/580,068 2017-11-01
PCT/US2018/058326 WO2019089672A1 (en) 2017-11-01 2018-10-31 Spirocyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2021501806A JP2021501806A (ja) 2021-01-21
JP2021501806A5 true JP2021501806A5 (https=) 2021-10-28
JP7228595B2 JP7228595B2 (ja) 2023-02-24

Family

ID=64332185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544335A Active JP7228595B2 (ja) 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしてのスピロ環化合物

Country Status (19)

Country Link
US (1) US11078198B2 (https=)
EP (1) EP3704114B1 (https=)
JP (1) JP7228595B2 (https=)
KR (1) KR102731924B1 (https=)
CN (1) CN111278821B (https=)
AR (1) AR113819A1 (https=)
AU (1) AU2018357878A1 (https=)
BR (1) BR112020008157A2 (https=)
CA (1) CA3081424A1 (https=)
CL (1) CL2020001140A1 (https=)
CO (1) CO2020005486A2 (https=)
EA (1) EA202091101A1 (https=)
ES (1) ES2933184T3 (https=)
IL (1) IL274322A (https=)
MX (1) MX2020004400A (https=)
PE (1) PE20201184A1 (https=)
SG (1) SG11202003825TA (https=)
TW (1) TW201922737A (https=)
WO (1) WO2019089672A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492211B2 (en) * 2019-11-29 2025-12-09 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof
JP7750836B2 (ja) * 2019-11-29 2025-10-07 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 三環式含窒素化合物の非晶質及びその用途
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN111592557A (zh) * 2020-05-09 2020-08-28 河北合佳医药科技集团股份有限公司 一种7-氨基-3-乙烯基头孢烷酸的一步法环保制备方法
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
KR102682408B1 (ko) * 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
KR20260032385A (ko) * 2024-08-28 2026-03-09 주식회사유한양행 Glp-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도
WO2026049509A1 (en) * 2024-08-28 2026-03-05 Yuhan Corporation Benzimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
SG162803A1 (en) * 2005-06-27 2010-07-29 Exelixis Inc Imidazole based lxr modulators
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Lxr 및 fxr 조절자
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6215230B2 (ja) 2012-01-16 2017-10-18 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
TWI714528B (zh) * 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MX2017008057A (es) 2014-12-18 2017-09-28 Novartis Ag Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
ES2862194T3 (es) 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途

Similar Documents

Publication Publication Date Title
JP2021501806A5 (https=)
US12331056B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
EP3630770B1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
AU2018374456B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2010249380B2 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
JP2021501805A5 (https=)
US20240059703A1 (en) Heterocyclic spiro compounds and methods of use
US8742098B2 (en) Inhibitors of Bruton's tyrosine kinase
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2021501218A5 (https=)
JP2014528482A5 (https=)
JP2021512954A5 (https=)
EP4288431A1 (en) Azabicyclic shp2 inhibitors
KR20180095595A (ko) 키나제 억제제로서의 트리시클릭 화합물 및 조성물
CN116171280A (zh) 酪蛋白激酶1δ调节剂
JPWO2019089670A5 (https=)
JPWO2019156987A5 (https=)
JPWO2019089664A5 (https=)
RU2846525C2 (ru) Ингибиторы shp2 фосфатазы и способы их применения
HK1168823A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
HK1168823B (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors